Freeze of Gait Market size was valued at USD 1.19 billion in 2022. The Freeze of Gait market industry is projected to grow from USD 1.22 Billion in 2023 to USD 1.99 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.86% during the forecast period (2023 - 2032). The Increasing prevalence of freeze of gait is one of the major driving factors for market growth.
Parkinson's disease is a disorder of the central nervous system that causes unintended or uncontrollable movements, such as stiffness, shaking, and difficulty with coordination and balance. These symptoms generally begin slowly and worsen over time. This may result in difficulty walking and talking. Freezing of gait (FoG) is one of the most debilitating motor symptoms in Parkinson's disease (PD) patients. Freezing of gait is an abnormal gait pattern that leads to a sudden inability to initiate or continue walking.
According to data published in Nature Journal, in the year 2022, FoG affected about 50% of Parkinson's disease patients and 80% of advanced Parkinson's disease patients. According to the Parkinson’s Foundation, currently around one million people in the US are living with Parkinson's disease (PD), and it is estimated that this number will rise to 1.2 million by 2030.
The Freeze of Gait Market segmentation, based on type, includes oral dopaminergic medication, wearable and walking aid devices, deep brain stimulation, and others. The wearable and walking aid devices segment is to hold the majority share in 2022 in the Freeze of Gait Market revenue due to easy to use, increasing disability case across the globe as well as increasing cases on uncontrollable moments are raise the demand of wearable and walking aid devices. Wearable and walking devices easily track the patient’s health and technological advancement in wearable and walking devices are further drive the growth of this segment.
October 2021: Teva collaborated with MODAG for licensing and development of neurodegenerative disease drug candidate. This collaboration enhances the company’s product portfolio and business in the market.
The Freeze of Gait Market segmentation is based on end user that includes hospitals, clinics, others. The hospitals segment has dominated the market in 2022 due to the easy accessibility, growing cases of advanced Parkinson disease, expansion of muscle disorder treatment capability. Furthermore, availability of advanced treatment facilities, proficient medical staff and rising patient pool are driving the growth of this segment in freeze of gait market.
November 2020: MedEXO Robotics, a Hong Kong-based robotics technology company had newly launched the ExoBeam walking device to relief patient with Parkinson’s disease and other movement disorders.
Figure 2: FREEZE OF GAIT MARKET, BY END USER, 2022 & 2032 (USD BILLION)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World.
The North America Freeze of Gait market is expected to account for USD 0.48 billion in 2022 and is expected to exhibit a 5.17% CAGR during the study period. This is attributed to the business presence of major key player, rising FDA approval, and increasing awareness about the medication and therapies, rising prevalence of Parkinson disease in the region drive the regional market growth during the forecast period.
In 2022, as per the Parkinson's Foundation, an estimated 90,000 suffered from Parkinson disease in the US people are affected by Freeze of Gait in the US, and this denotes a steep 50% growth from the earlier estimated rate of 60,000 diagnoses annually which is contributing to market growth over the forecast period.
Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3: GLOBAL FREEZE OF GAIT SHARE (%) BY REGION 2022
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe Freeze of Gait market is expected to account for the second-largest market share due to the increasing healthcare expenditure, rising demand for advanced therapeutics, and increasing geriatric population lead to risk of Parkinson disease associated freeze of gait which drive the growth of freeze gait in Europe region.
Accessibility to advanced technology for disease diagnosis, the rising geriatric population prone to Freeze of Gait is driving up demand for effective treatment & therapeutics and increasing awareness about the freeze of gait. For instance, At present time more than 1.2 million people suffering from Parkinson’s in Europe and this number is forecast to double by 2030. In addition, The cost per Parkinson’s patient amounts to approximately USD 12,058 on average across Europe, and a cost to Europe of USD 15.24 billion annually Thus, increasing treatment cost per patient in Europe, rising research and development activity positively impact on the growth of freeze of gait market. Additionally, favorable government support for better treatment facility are boosting the growth of the Freeze of Gait market in Europe.
The Asia-Pacific freeze of gait market is expected to grow at a CAGR of 6.03% from 2023 to 2032. This is due to factors such as rising medical facility, increasing government initiative for freeze gait treatment, presence of large patient pool of Parkinson disease associated with freeze of gait are positively impact on the growth of freeze of gait market in Asia-Pacific region. Furthermore, availability of cheap labour cost, increasing interest of major key players for investment in Asia-Pacific region are further drive the growth of this market.
The Rest of the World includes the Middle East, Africa, and Latin America. Middle East hold the major market share in middle east and Africa region due to rising government support for business establishment of key players, rising incidence of freeze of gait limited increasing number of research companies and subsidiaries involved in R&D, and increasing initiatives are taken by Middle East countries to develop their healthcare infrastructure. Moreover, growing awareness and demand from the general population for effective treatments are likely to favor market growth.
Freeze of Gait Key Market Players & Competitive Insights
The freeze of gait market is distinguished by the presence of numerous global, regional, and local players catering to the increasing research funding and collaborations, and growing Parkinson’s diseases. Because of increased adoption of advanced medical technologies and continuous development by companies, the freeze of gait market is becoming more profitable.
Several factors are driving market growth, including increasing prevalence of Parkinson’s disease and other related diseases, the growing geriatric population, and increasing investment in R&D. Furthermore, the freeze of gait market is highly competitive, with players competing, collaborating, and investing heavily in research and development to gain a significant market share. The market is expanding with rising investment by key players. The growth of key market players is dependent on market conditions, government support, and industry development.
Key players in the Freeze of Gait Market focus on expanding regionally and improving their product quality and delivery. Although international players dominate the market, regional players with small market shares also have a considerable presence. The international players may strengthen their presence through acquisitions and collaborative agreements during the forecast period. It has also been forecasted that improvement of the global economic scenario combined with efforts to enhance product delivery globally is fueling the market growth, thereby making it an ideal time for new players with innovative products to enter the market and increase the market share. The market is moderately fragmented due to rising competition, product launches, increased collaborative partnerships, and other strategic decisions to achieve operational efficiency.
Key Companies in the Freeze of Gait Market Include
Freeze of Gait Industry Developments
October 2021: Teva collaborated with MODAG for licensing and development of neurodegenerative disease drug candidate. This collaboration enhances the company’s product portfolio and business in the market.
September 2021: Gondola Medical Technologies collaborated with Mount Sinai Health System (US) to enhance the scientific understanding of Automated Peripheral Mechanical Stimulation (AMPS) therapy.
| Report Attribute/Metric | Details |
| Â Market Size 2022 | USD 1.19 billion |
| Â Market Size 2023 | USD 1.22 billion |
| Market Size 2032 | USD 1.99 billion |
| Compound Annual Growth Rate (CAGR) | 4.86% (2023- 2032) |
| Base Year | 2022 |
| Forecast Period | 2023- 2032 |
| Historical Data | 2019, 2020, and 2021 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Teva Pharmaceuticals (Israel), Sun Pharmaceutical Industries Ltd (India), Viatris Inc (US), Gondola Medical Technologies SA (Switzerland), Gyenno Technologies Co., Ltd. (China), Beats Medical Limited (Ireland), Agilitas (Australia), Walk with Path (Vesterbro), MedEXO Robotics (Hong Kong), Ustep (US) |
| Key Market Opportunities | ·      Technological advancement and new product launches |
| Key Market Dynamics | ·      Increasing investment in R&D |
Freeze of Gait Market Highlights:
Frequently Asked Questions (FAQ) :
The Freeze of Gait Market is anticipated to reach USD 1.19 billion at a CAGR of 4.86% during the forecast period of 2023 to 2032.
The US freeze of gait market is anticipated to reach USD 0.40 billion at a CAGR of 5.26% during the forecast period of 2023 to 2032.
The Freeze of Gait Market is expected to register a CAGR of 4.86% during the forecast period of 2023 to 2032.
The North America freeze of gait market accounted for the largest market share during the study period.
Teva Pharmaceuticals (Israel), Sun Pharmaceutical Industries Ltd (India), Viatris Inc (US), Gondola Medical Technologies SA (Switzerland), Gyenno Technologies Co., Ltd. (China), Beats Medical Limited (Ireland), Agilitas (Australia), Walk with Path (Vesterbro), MedEXO Robotics (Hong Kong), Ustep (US).
The wearable and walking aid devices segment held the majority share in 2022 contributing to around 45% with respect to the Freeze of Gait Market.
The hospitals segment held the majority share in 2022 contributing to over 60% with respect to the Freeze of Gait Market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
